2021
DOI: 10.1016/j.phrs.2021.105695
|View full text |Cite
|
Sign up to set email alerts
|

Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(30 citation statements)
references
References 112 publications
0
30
0
Order By: Relevance
“…Based on the findings reported here, revisiting integrin targeting in patient populations selected on the basis of EMT-related expression signatures might be warranted. Based on evidence reported here that HDAC2 derepresses ITGA1 in mesenchymal lung adenocarcinoma, such approaches could include HDAC2 inhibitors that are under clinical development ( 41 ). Given that EMT is a key driver of acquired resistance to kinase inhibitors in lung adenocarcinoma ( 39 ), ITGA1 targeting strategies could address an immediate clinical need.…”
Section: Discussionmentioning
confidence: 99%
“…Based on the findings reported here, revisiting integrin targeting in patient populations selected on the basis of EMT-related expression signatures might be warranted. Based on evidence reported here that HDAC2 derepresses ITGA1 in mesenchymal lung adenocarcinoma, such approaches could include HDAC2 inhibitors that are under clinical development ( 41 ). Given that EMT is a key driver of acquired resistance to kinase inhibitors in lung adenocarcinoma ( 39 ), ITGA1 targeting strategies could address an immediate clinical need.…”
Section: Discussionmentioning
confidence: 99%
“…This may due to the fact that Decitabine directly inhibits DNMT-1, while Azacitidine needs to compete with cytidine to bind to DNMT-1. Trichostatin A (TSA) is an HDAC inhibitor (79)(80)(81), which has nothing to do with DNA methylation. TSA treatment of U251 or U87 cells does not affect the methylation rate of the miR-338-5p promoter region in the cells.…”
Section: Discussionmentioning
confidence: 99%
“…Mechanistically, HDAC6 deacetylates Lys120 on p53, thereby inactivating the pro-apoptotic function of p53 ( 190 ). However, not all HDAC subtypes are abnormally expressed in all malignancies, so pan-inhibition of HDAC is not an effective way to treat cancer ( 191 ). Besides, because of its poor activity as a single agent, HDACis have been investigated along with radiotherapy, chemotherapy, and other epigenetic drugs.…”
Section: Therapeutic Targeting Of the Oc Epigenomementioning
confidence: 99%